(Reuters) – Relmada Therapeutics’ depression treatment is “unlikely” to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee’s analysis. The treatment, REL-1017, also known as esmethadone, was being tested as an adjunctive for major depressive disorder (MDD) to be used in combination with other approved anti-depressants. […]
Health
Relmada’s depression drug unlikely to meet main trial goal, analysis shows
Audio By Carbonatix
(Reuters) – Relmada Therapeutics’ depression treatment is “unlikely” to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee’s analysis.
The treatment, REL-1017, also known as esmethadone, was being tested as an adjunctive for major depressive disorder (MDD) to be used in combination with other approved anti-depressants.
“Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program,” CEO Sergio Traversa said in a statement.
Relmada had about $54.1 million in cash and its equivalents as of Sept. 30.
(Reporting by Christy Santhosh and Kamal Choudhury in Bengaluru)